Utility and Validation's Study of a Smartphone Application for Periodic Paralysis
NCT05976958 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2
Last updated 2026-03-03
Summary
Periodic paralyses (PP) are rare genetic disorders characterized by the occurrence of acute and reversible episodes of muscle weakness. Their episodic and highly variable nature makes it difficult to gather the necessary information for monitoring and therapeutic adaptation. Patients struggle to accurately report the number, duration, severity, and triggers of their attacks that have occurred between two consultations.
Currently, there are no validated scales or tools for precisely and standardizedly assessing paralytic episodes. Ecological Momentary Assessment (EMA) is a real-time data collection method used in research, historically on paper forms and then on expensive and cumbersome electronic devices (PDAs). The widespread use of smartphones opens up a new avenue in this field, and the use of a mobile application as a real-time data collection tool could be perfectly applicable to these conditions with episodic expression. It is hypothesized that systematic and real-time collection of paralysis episode characteristics will improve the quality and accuracy of the collected data, thus enhancing clinicians' understanding of the condition and patient management. Moreover, little is known about the medical and social impact of the disease. To address these specific issues, the investigators propose a study of patients with "Periodic Paralyses" based on prospective collection of clinical and medico-social data during routine consultations and in real-time during paralytic episodes using a dedicated smartphone application developed by Ad Scientiam in collaboration with Dr. Savine Vicart, the study coordinator.
The primary objective of this study is to evaluate the benefit of a smartphone application specifically developed for patients with periodic paralyses to collect real-time information and improve the quality of collected data regarding the characteristics of paralysis episodes (number, duration, intensity, triggering factors, location, treatment) compared to the retrospective questionnaire typically used in consultations.
The secondary objective is to assess the impact of this new data collection method on the medical management of patients.
Conditions
- Periodic Paralyses
Sponsors & Collaborators
-
Institut National de la Santé Et de la Recherche Médicale, France
lead OTHER_GOV
Principal Investigators
-
Savine Vicart · INSERM U1127 - IHU- ICM
Eligibility
- Min Age
- 12 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-07-25
- Primary Completion
- 2019-08-02
- Completion
- 2019-08-02
Countries
- France
Study Locations
More Related Trials
-
A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
NCT01281631 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 3 Study of Dexpramipexole in ALS
NCT01281189 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury
NCT01484184 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Trehalose Administration in Subjects With Spastic Paraplegia 11 (3AL-SPG11)
NCT04912609 ·Status: COMPLETED
-
Bumetanide in Hypokalaemic Periodic Paralysis
NCT02582476 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)
NCT00694941 ·Status: COMPLETED ·Phase: PHASE2
-
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
NCT05407324 ·Status: RECRUITING ·Phase: PHASE2
-
Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
NCT02960217 ·Status: TERMINATED ·Phase: PHASE3
-
Study to Evaluate Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy
NCT00528268 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)
NCT00647296 ·Status: COMPLETED ·Phase: PHASE2
-
A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)
NCT06069934 ·Status: NO_LONGER_AVAILABLE
-
IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis
NCT00488839 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Tolerability of Perampanel in Cervical Dystonia
NCT02131467 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT00403104 ·Status: COMPLETED ·Phase: PHASE2
-
Understanding Individual Variability in Neuronal Signal Transmission to Target Organs in Health and Disease
NCT06912048 ·Status: RECRUITING ·Phase: NA
-
A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury
NCT00557973 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy.
NCT00605930 ·Status: COMPLETED ·Phase: NA
-
Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)
NCT02784535 ·Status: COMPLETED ·Phase: PHASE2
-
Sinusoidal Galvanic Vestibular Stimulation for Neurogenic Orthostatic Hypotension / Syncope
NCT04976101 ·Status: WITHDRAWN ·Phase: NA
-
Trial of Ropinirole in Motor Recovery After Stroke
NCT00221390 ·Status: COMPLETED ·Phase: PHASE2
-
Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO)
NCT00931164 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day
NCT00596115 ·Status: TEMPORARILY_NOT_AVAILABLE
-
Use of Dalfampridine in Primary Lateral Sclerosis
NCT02868567 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
ALS Phase II Study of NX210c
NCT06365216 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT03127514 ·Status: COMPLETED ·Phase: PHASE2